Jean-Loup Romet-Lemonne

JEAN-LOUP ROMET-LEMONNE is President and Chief Executive Officer of
Immuno-Designed Molecules, SA (IDM), a biopharmaceutical company he
founded in 1993. Today, IDM has 88 employees and is developing cancer
vaccines for the treatment of ovarian, prostate and bladder cancer as
well as leukemia and melanoma. Dr. Romet-Lemonne has 15 years’
experience in the academic medical community, including 12 years in the
French university hospital system, and four years at Harvard
University’s Department of Cancer Biology. He obtained his Medical
degree from the University of Tours, and has attended Management
programs at HEC and Stanford University.